(Total Views: 1128)
Posted On: 05/02/2024 5:34:13 PM
Post# of 148870
CYDY's got many "Bites at the apple" remaining --
Hi SamaGong,
The Dr. Jay quote you referenced was him speaking about CYDY having a finite number of opportunities remaining specifically in the HIV realm. Fortunately the forthcoming HIV inflammation trial (designed in close conjunction with the FDA) gives CYDY a great shot at success in a huge, empty lane that CYDY will potentially own. Not to mention once Leron proves itself in HIV inflammation, Leronlimab can be used as a potent, game-changing anti-inflammatory in countless other diseases.
In terms of the numerous other bites CYDY has left at the apple besides HIV inflammation (and inflammation in general), in addition to the Glioblastoma trial, Dr. Jay has referenced Leronlimab's possible role in Alzheimer's, NASH, Oncology and Long-Covid.
Not to mention OHM's list of even MORE bites at the apple for CYDY and their incredible drug, Leronlimab. The future is bright, fellow longs!
OHM'S List:
Leronlimab - Disease List (currently 90)
An incomplete list of potential treatment targets for leronlimab.
AA Amyloidosis
Acute Respiratory Distress Syndrome
Allergies (anaphylactic shock)
Alopecia Areata
Alzheimer's
Amyotrophic Lateral Sclerosis
Angioedema
Anthrax
Aplastic Anemia
Asthma
Atherosclerosis
Atopic Dermatitis
Cancer
Castleman Disease
Celiac Disease
Coeliac Disease
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Kidney Disease (due to inflammation)
Chronic Traumatic Encephalopathy
COPD
COVID-19 (and other coronaviruses)
COVID-19 longhaulers syndrome (PASC)
Crohn's Disease
Colitis
Cystic Fibrosis (anti-inflammatory in combo with CFTR modulators)
Dermatomyositis
Diabetes (type 1 and 2)
Duchenne Muscular Dystrophy
Emphysema
Endometriosis
Eosinophilic Esophagitis
Epilepsy (reduction in frequency and severity)
Fibromyalgia
FMF Related Amyloidosis
Fragile X Syndrome
Gout
Grave’s Disease
Guillain-Barre Syndrome
GVHD
Hashimoto’s Thyroiditis
Henoch–Schönlein Purpura
Hepatitis (autoimmune)
HIV
Huntington's Disease
Idiopathic Pulmonary Fibrosis
Immune Thrombocytopenia
Inclusion Body Myositis
Inflammatory Bowel Disease
Influenza (severe)
Kawasaki Syndrome
Lambert-Eaton Syndrome
Lewy Body Dementia
Lupus
Lyme Disease
Lymphedema
Marshall’s syndrome (PFAPA)
Mesenteric Panniculitis
Miller Fisher Syndrome
Multiple Sclerosis
Myasthenia Gravis
Myocarditis
NASH
Necrotizing Autoimmune Myopathy
Neurofibromatosis
Osteoarthritis
Osteomyelitis
Parkinson's Disease
Pemphigus
Peyronie's Disease (treatment of underlying autoimmune condition)
Pneumonia
Polymyositis
Post-Myocardial Infarction Syndrome
Psoriasis
Pulmonary Arterial Hypertension
Pulmonary Fibrosis
Rett Syndrome
Rheumatic Fever
Rheumatoid Arthritis
Sarcoidosis
Scleroderma
Sepsis
Sickle Cell Disease (anti-inflammatory and anti-hypercoagulability effect)
Sjogren’s Syndrome
Still’s Disease
Stroke
Trigeminal Neuralgia
Tuberculosis
Vasculitis
Wegener’s Granulomatosis
I remain... #BULLISH
P.S. This one's for you, SamaGong: https://www.youtube.com/watch?v=T-UK_d0fQYM
Hi SamaGong,
The Dr. Jay quote you referenced was him speaking about CYDY having a finite number of opportunities remaining specifically in the HIV realm. Fortunately the forthcoming HIV inflammation trial (designed in close conjunction with the FDA) gives CYDY a great shot at success in a huge, empty lane that CYDY will potentially own. Not to mention once Leron proves itself in HIV inflammation, Leronlimab can be used as a potent, game-changing anti-inflammatory in countless other diseases.
In terms of the numerous other bites CYDY has left at the apple besides HIV inflammation (and inflammation in general), in addition to the Glioblastoma trial, Dr. Jay has referenced Leronlimab's possible role in Alzheimer's, NASH, Oncology and Long-Covid.
Not to mention OHM's list of even MORE bites at the apple for CYDY and their incredible drug, Leronlimab. The future is bright, fellow longs!
OHM'S List:
Leronlimab - Disease List (currently 90)
An incomplete list of potential treatment targets for leronlimab.
AA Amyloidosis
Acute Respiratory Distress Syndrome
Allergies (anaphylactic shock)
Alopecia Areata
Alzheimer's
Amyotrophic Lateral Sclerosis
Angioedema
Anthrax
Aplastic Anemia
Asthma
Atherosclerosis
Atopic Dermatitis
Cancer
Castleman Disease
Celiac Disease
Coeliac Disease
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Kidney Disease (due to inflammation)
Chronic Traumatic Encephalopathy
COPD
COVID-19 (and other coronaviruses)
COVID-19 longhaulers syndrome (PASC)
Crohn's Disease
Colitis
Cystic Fibrosis (anti-inflammatory in combo with CFTR modulators)
Dermatomyositis
Diabetes (type 1 and 2)
Duchenne Muscular Dystrophy
Emphysema
Endometriosis
Eosinophilic Esophagitis
Epilepsy (reduction in frequency and severity)
Fibromyalgia
FMF Related Amyloidosis
Fragile X Syndrome
Gout
Grave’s Disease
Guillain-Barre Syndrome
GVHD
Hashimoto’s Thyroiditis
Henoch–Schönlein Purpura
Hepatitis (autoimmune)
HIV
Huntington's Disease
Idiopathic Pulmonary Fibrosis
Immune Thrombocytopenia
Inclusion Body Myositis
Inflammatory Bowel Disease
Influenza (severe)
Kawasaki Syndrome
Lambert-Eaton Syndrome
Lewy Body Dementia
Lupus
Lyme Disease
Lymphedema
Marshall’s syndrome (PFAPA)
Mesenteric Panniculitis
Miller Fisher Syndrome
Multiple Sclerosis
Myasthenia Gravis
Myocarditis
NASH
Necrotizing Autoimmune Myopathy
Neurofibromatosis
Osteoarthritis
Osteomyelitis
Parkinson's Disease
Pemphigus
Peyronie's Disease (treatment of underlying autoimmune condition)
Pneumonia
Polymyositis
Post-Myocardial Infarction Syndrome
Psoriasis
Pulmonary Arterial Hypertension
Pulmonary Fibrosis
Rett Syndrome
Rheumatic Fever
Rheumatoid Arthritis
Sarcoidosis
Scleroderma
Sepsis
Sickle Cell Disease (anti-inflammatory and anti-hypercoagulability effect)
Sjogren’s Syndrome
Still’s Disease
Stroke
Trigeminal Neuralgia
Tuberculosis
Vasculitis
Wegener’s Granulomatosis
I remain... #BULLISH
P.S. This one's for you, SamaGong: https://www.youtube.com/watch?v=T-UK_d0fQYM
(17)
(0)Scroll down for more posts ▼
